High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
4 clinical trials · Condition
◉ Watch High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
| Record | Firm | Date |
|---|---|---|
| Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma (NCT05276167) | Henan Cancer Hospital | 2022-06-06 |
| Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study (NCT05418309) | Tianjin Medical University Second Hospital | 2021-12-27 |
Track High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.